Actionable news
0
All posts from Actionable news
Actionable news in ADMP: ADAMIS PHARMACEUTICALS CORPORATION,

Adamis Pharmaceuticals Corporation 8-K

The following excerpt is from the company's SEC filing.

Exhibit 99.1

Adamis Pharmaceuticals Completes Acquisition of US Compounding

Adamis Pharmaceuticals Corporation

(NASDAQ: ADMP) (“Company” or “Adamis”) announced today that it has successfully completed its previously announced acquisition (the “Acquisition”) of US Compounding, Inc. (“USC”). Upon the closing of this transaction, USC has become a wholly-owned subsidiary of Adamis.

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “We are pleased to have completed this transformational acquisition that will expand our product portfolio, provid e immediate revenues, as well as significantly increase our manufacturing, sales and marketing capabilities. The combination will now position us to better commercialize our pipeline products upon approval and diversify our revenue mix.

Our Epinephrine Pre-filled Syringe (“PFS”) has an FDA agency action date (PDUFA date) of June 4, 2016. The potential revenues from the PFS combined with the anticipated cash flows from USC, should put Adamis in a strong financial position.”

Please see Adamis’ Form 8K filed with the Securities and Exchange Commission for additional details on the transaction.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of allergy and respiratory disease. The Company’s current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the...


More